AŞAysel Büşra Şişman

Aysel Büşra Şişman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aysel Büşra Şişman has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Increased serum transferrin receptor 1 levels are associated with severity of acute ischemic stroke in patients with Covid-19 pneumonia

    by Zülfikar Memiş, Selen Soylu, Muhammet Duran Bayar, Aysel Büşra Şişman, Nuray Sancar, Erdem Tüzün, Birgül Baştan

    Background and purpose – Acute ischemic stroke (AIS) is often encountered during the clinical course of coronavirus disease 2019 (COVID-19) infection. Accumulated evidence has indicated involvement of ferroptosis in AIS. Our aim was to investigate the association between serum levels of ferroptosis markers and severity of AIS in COVID-19 patients. Methods – Twenty-nine consecutively enrolled COVID-19+ pneumonia patients with AIS due to middle cerebral artery (MCA) occlusion, 25 COVID-19+ pneumonia patients without AIS and 26 AIS patients without COVID-19 infection were included. Serum levels of ferroptosis markers glutathione peroxidase 4 (GPX4), dipeptidylpeptidase-4 (DPP4) and soluble transferrin receptor 1 (sTFR1) were measured by ELISA. Results – While serum GPX4 levels were comparable among groups, COVID-19 patients with and without AIS showed significantly increased serum sTFR1 levels and COVID-19 patients with AIS showed significantly decreased serum DPP4 levels. In patients with COVID-19 and AIS, serum levels of DPP4 and sTFR1 respectively showed negative and positive correlation with levels of D-dimer and/or C-reactive protein (CRP). Levels of ferroptosis markers did not correlate with clinical/prognostic features of pneumonia or AIS. Nevertheless, COVID-19 patients with higher (≥ 131 pg/ ml) sTFR1 levels were more likely to exhibit severe pneumonia, increased clinical severity of AIS (assessed by the national institutes of health stroke and modified Rankin scales) and elevated D-dimer/CRP levels. Our results indicate TFR1 as a potential role player in both COVID-19 pneumonia and arterial thrombosis associated with COVID-19 infection. The biomarker utility of sTFR1 in these disorders should further be evaluated. Conclusion – Our results suggest that AIS associated with COVID-19 have a different pathogenesis.

  • Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study

    by Aysel Büşra Şişman, Merve Savaş, Gizem Koral, Muhammet Duran Bayar, Oğuz Yildiz, Aytül Mutlu, Vuslat Yilmaz, Erdem Tüzün, Özlem Çokar

    Background and purpose – The role of synaptic dysfunction in focal epilepsy of unknown cause is not well understood. Neurogranin is a post-synaptic protein used as a biomarker of synaptic disintegration in patients with dementia. Methods – To evaluate the association between synaptic loss, cognitive impairment and seizure activity in epilepsy, we collected sera of 51 patients with focal epilepsy of unknown cause, 26 with frontal lobe epilepsy (FLE) and 25 with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLEHS), and 25 healthy controls. Serum neurogranin levels were measured by ELISA and we sought for potential correlations between neurogranin levels versus clinical features, cognitive test and quality of life scores of the patients. Results – Neurogranin levels were significantly reduced in MTLE-HS patients as compared to FLE patients and healthy controls but were not correlated with any of the clinical and cognitive variables. Both FLE and MTLE-HS patients with treatment resistance showed significantly reduced neurogranin levels. Conclusion – Our results suggest that MTLE-HS patients suffer from reduced synaptic protein production rather than increased synaptic breakdown. Reduction of neurogranin is associated with resistance to anti-epileptic treatment implying the role of this protein in the control of seizures. Neurogranin might serve as a biomarker for monitorization of seizure activity in focal epilepsies.


  • Increased neuropil antibody prevalence in COVID-19 patients with acute ischemic stroke

    by Birgül Baştan, Ece Erdağ Turgeon, Elif Şanlı, Muhammet Duran Bayar, Aysel Büşra Şişman, Miray Atacan Yaşgüçlükal, Cem İ̇sMail Küçükali, Erdem Tüzün, Sefer Günaydın

    COVID-19 infection is associated with an increased risk of acute ischemic stroke (AIS). Although the underlying mechanisms are largely unknown, autoimmunity has been implicated as a potential role player. To investigate the presence and clinical impact of neuronal cell surface antibodies in COVID-19 associated AIS, patients with COVID-19 pneumonia and AIS (n = 30), COVID-19 pneumonia without AIS (n = 32) and AIS without COVID-19 infection (n = 27) were recruited. Serum anti-neuronal antibodies directed against well-characterized and novel cell surface antibodies were evaluated by cell-based assays and indirect immunohistochemistry, respectively. None of the recruited patients displayed well-characterized neuronal cell surface antibodies. Ten patients in the COVID-19 pneumonia with AIS group and three patients in the COVID-19 pneumonia without AIS group exhibited antibodies to neuropil of hippocampus and cerebellum. Neuropil-antibody positive patients showed trends towards milder clinical severity and reduced blood levels of inflammation factors. Our results confirm the presence of neuropil antibodies in patients with COVID-19 infection and identify a putative antibody-driven association between AIS and COVID-19. The antigenic targets and potential pathogenic action of these antibodies need to be further explored.